ZYME

26.68

0.37% -0.10

Pre-mercato: 27.06 0.38 +1.42%

Zymeworks Inc. (ZYME)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Forum Previsione

Precedente Chiudi:

$26.78

Aprire:

$27.02

Volume 24 ore:

412.70K

Relative Volume:

0.66

Capitalizzazione di mercato:

$1.98B

Reddito:

$105.97M

Utile/perdita netta:

$-81.13M

Rapporto P/E:

-24.72

EPS:

-1.0791

Flusso di cassa netto:

$-35.43M

1 W Prestazione:

-4.51%

1M Prestazione:

+3.41%

6M Prestazione:

+47.81%

1 anno Prestazione:

+107.63%

Intervallo 1D:

$26.12

$27.33

Intervallo di 1 settimana:

$26.12

$28.18

Portata 52W:

$10.86

$29.75

Zymeworks Inc. Stock (ZYME) Company Profile

Nome

Zymeworks Inc.

Settore

Healthcare (1106)

Industria

Biotechnology (615)

Telefono

604-678-1388

Indirizzo

1385 West 8th Avenue, Suite 540, Vancouver, BC

Dipendente

170

Cinguettio

@ZymeworksInc

Prossima data di guadagno

2026-05-07

Ultimi documenti SEC

ZYME's Discussions on Twitter

Compare ZYME vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ZYME Zymeworks Inc.	26.68	1.98B	105.97M	-81.13M	-35.43M	-1.0791
VRTX Vertex Pharmaceuticals Inc	424.36	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.06B	5.36B	287.73M	924.18M	2.5229

Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-12-12	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2025-12-03	Iniziato	Citizens JMP	Mkt Outperform
2025-10-24	Ripresa	Wells Fargo	Equal Weight
2025-10-14	Aggiornamento	H.C. Wainwright	Neutral → Buy
2025-10-10	Iniziato	B. Riley Securities	Buy
2025-05-20	Iniziato	TD Cowen	Buy
2024-12-16	Aggiornamento	JP Morgan	Neutral → Overweight
2024-11-07	Aggiornamento	Leerink Partners	Market Perform → Outperform
2024-11-01	Downgrade	Wells Fargo	Overweight → Equal Weight
2023-03-21	Ripresa	Wells Fargo	Overweight
2023-01-04	Reiterato	H.C. Wainwright	Neutral
2022-12-20	Aggiornamento	Jefferies	Hold → Buy
2022-11-01	Downgrade	H.C. Wainwright	Buy → Neutral
2022-10-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
2022-10-04	Ripresa	Wells Fargo	Overweight
2022-05-05	Aggiornamento	Guggenheim	Neutral → Buy
2022-03-15	Iniziato	Evercore ISI	Outperform
2021-12-10	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2021-11-17	Ripresa	Guggenheim	Neutral
2021-10-07	Iniziato	Jefferies	Hold
2021-03-31	Iniziato	Credit Suisse	Outperform
2021-02-25	Downgrade	SVB Leerink	Outperform → Mkt Perform
2021-02-08	Ripresa	H.C. Wainwright	Buy
2021-01-25	Downgrade	Citigroup	Buy → Neutral
2020-09-29	Ripresa	JP Morgan	Neutral
2020-08-06	Iniziato	SVB Leerink	Outperform
2020-01-10	Iniziato	Wolfe Research	Outperform
2019-12-09	Iniziato	JP Morgan	Neutral
2019-11-25	Iniziato	H.C. Wainwright	Buy
2019-11-20	Iniziato	Guggenheim	Buy
2019-09-30	Aggiornamento	Raymond James	Outperform → Strong Buy
2019-08-30	Iniziato	Stifel	Buy
2019-07-18	Iniziato	Deutsche Bank	Buy
2018-05-11	Aggiornamento	Barclays	Underweight → Equal Weight
2018-03-19	Iniziato	Raymond James	Outperform

Mostra tutto

Zymeworks Inc. Borsa (ZYME) Ultime notizie

May 05, 2026

Pictet Asset Management Holding SA Invests $1.97 Million in Zymeworks Inc. $ZYME - MarketBeat

May 05, 2026

May 03, 2026

Kornitzer Capital Management Inc. KS Takes $2.34 Million Position in Zymeworks Inc. $ZYME - MarketBeat

May 03, 2026

Apr 28, 2026

H.C. Wainwright reiterates Zymeworks stock rating on FDA filing By Investing.com - Investing.com India

Apr 28, 2026

Zymeworks Inc at JPMorgan Healthcare Conference Transcript - GuruFocus

Apr 28, 2026

H.C. Wainwright reiterates Zymeworks stock rating on FDA filing - Investing.com UK

Apr 28, 2026

Zymeworks Highlights Royalty-Fueled Pivot at Bloom Burton, Eyes Multibillion-Dollar Ziihera - Yahoo Finance

Apr 26, 2026

Apr 23, 2026

Zymeworks stock hits 52-week high at $28.50 By Investing.com - Investing.com India

Apr 23, 2026

Zymeworks Inc. (NASDAQ:ZYME) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Apr 23, 2026

Apr 22, 2026

Zymeworks (NASDAQ:ZYME) Hits New 1-Year HighWhat's Next? - MarketBeat

Apr 22, 2026

Zymeworks stock hits 52-week high at $28.50 - Investing.com

Apr 22, 2026

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026 - wahanariau.com

Apr 22, 2026

Stifel reiterates Zymeworks stock rating on ADC data strength - Investing.com UK

Apr 22, 2026

Apr 21, 2026

Zymeworks reports phase 1 trial results for ovarian cancer drug By Investing.com - Investing.com South Africa

Apr 21, 2026

PERCEPTIVE ADVISORS LLC Expands Stake in Zymeworks Inc with Sign - GuruFocus

Apr 21, 2026

Zymeworks reports phase 1 trial results for ovarian cancer drug - Investing.com

Apr 21, 2026

Zymeworks (ZYME) Broadens ADC Toolkit at AACR 2026 Is Its Oncology Platform Taking Shape? - simplywall.st

Apr 21, 2026

Experimental Zymeworks cancer drug shows 61% response in ovarian study - Stock Titan

Apr 21, 2026

AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new data - BioSpace

Apr 21, 2026

Zymeworks Inc stock (US98985W1080): Is its bispecific antibody platform resilient enough for biotech - AD HOC NEWS

Apr 21, 2026

Apr 19, 2026

A Look At Zymeworks (ZYME) Valuation As AACR 2026 ADC Data Draws Investor Attention - Sahm

Apr 19, 2026

Apr 18, 2026

Zymeworks presents preclinical data on ADC pipeline at AACR By Investing.com - Investing.com Australia

Apr 18, 2026

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform - wahanariau.com

Apr 18, 2026

Apr 17, 2026

Zymeworks presents preclinical data on ADC pipeline at AACR - Investing.com

Apr 17, 2026

Zymeworks Inc. - Via Ritzau

Apr 17, 2026

Zymeworks (ZYME) price target increased by 12.53% to 40.88 - MSN

Apr 17, 2026